Pomerantz files class action against Regeneron over Fianlimab disclosures
Pomerantz LLP said it filed a class action against Regeneron Pharmaceuticals and told investors with losses during the class period that they have until Sept. 14, 2026, to seek appointment as lead plaintiff.
Pomerantz LLP said on Aug. 20, 2026, that it filed a securities class action against Regeneron Pharmaceuticals Inc. and told investors who bought or otherwise acquired Regeneron securities during the class period that they have until Sept. 14, 2026, to ask the court to appoint them as lead plaintiff.
According to the law firm’s notice, the lawsuit centers on two company disclosures tied to stock moves. Pomerantz said the case concerns whether Regeneron and certain officers and/or directors engaged in securities fraud or other unlawful business practices.
According to the release, Regeneron disclosed on April 29, 2026, during its first-quarter earnings call, that the Phase III Fianlimab-Libtayo Study had been altered to expand the number of patients eligible for analysis of progression-free survival. Pomerantz said the stock fell $45.41, or 6.21%, to close at $686.36 that day.
The firm said Regeneron later issued a May 15, 2026 press release stating that the Phase 3 trial of Fianlimab did not reach statistical significance for the primary endpoint of improvement in progression-free survival, or PFS. Pomerantz said the stock then fell $68.57, or 9.82%, to close at $629.68 on May 16, 2026.
The notice says investors may seek lead plaintiff appointment by the Sept. 14 deadline. It says investors who inquire by email should include their mailing address, telephone number and the number of shares purchased. Pomerantz also said a copy of the complaint can be obtained at its website.
The release includes background on the law firm, saying Pomerantz has offices in New York, Chicago, Los Angeles, London, Paris and Tel Aviv and has operated for more than 85 years.
The court will next select a lead plaintiff. The notice says investors with losses during the class period may contact Danielle Peyton at Pomerantz for more information.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
View the Web StoryA visual, tap-through version of this reportThis is the AMP version of the article. Read the full article on Atlas Watchline.